Cyclerion Therapeutics, Inc. carries no debt; cash flow comfortably covers obligations.

Cyclerion Therapeutics, Inc.'s free cash flow has increased -23.52% from $-4.33M last year to $-3.31M, signaling increasing performance

Cyclerion Therapeutics, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Cyclerion Therapeutics, Inc. has insufficient data to evaluate this check.

Cyclerion Therapeutics, Inc. has a net cash position, so leverage is healthy.

Cyclerion Therapeutics, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Cyclerion Therapeutics, Inc.'s profit margin has decreased (130.95%) in the last year from -152.85% to -353.00%, signaling decreasing performance

Cyclerion Therapeutics, Inc.'s short-term assets of $4.63M exceed its short-term liabilities of $900.00K

Cyclerion Therapeutics, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Cyclerion Therapeutics, Inc.'s return on equity of -87.96%, is lower than 15.00%, indicating bad performance

Cyclerion Therapeutics, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Cyclerion Therapeutics, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Cyclerion Therapeutics, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Cyclerion Therapeutics, Inc. has negative free cash flow, indicating cash burn

Cyclerion Therapeutics, Inc.'s yearly earnings has decreased 15.41% since last year from $-3.06M to $-3.53M, signaling decreasing performance

Cyclerion Therapeutics, Inc.'s yearly revenue has increased 3.70% since last year from $2.00M to $2.07M, signaling increasing performance

ROIC -134.15% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Cyclerion Therapeutics, Inc.'s 3-year revenue CAGR of 91.14% is positive, indicating growing revenue over the past 3 years

Cyclerion Therapeutics, Inc. had revenue growth in 3 out of 5 years, indicating consistent revenue performance

Cyclerion Therapeutics, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Cyclerion Therapeutics, Inc. has insufficient data to evaluate this check.

Cyclerion Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cyclerion Therapeutics, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Cyclerion Therapeutics, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Cyclerion Therapeutics, Inc. has insufficient data to evaluate this check.

Cyclerion Therapeutics, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Cyclerion Therapeutics, Inc. has a price-to-book ratio of 2.99x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Cyclerion Therapeutics, Inc. has a price-to-sales ratio of 8.01x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue